RTRS - FCA- TEMPORARILY SUSPENDS SHARES IN AVEVA GROUP PLC FROM OFFICIAL LIST EFFECTIVE FROM 13/06/2016 2:00 PM AT REQUEST OF COMPANY PENDING AN ANNOUNCEMENT
Gapping down
In reaction to disappointing earnings/guidance: SYUT -6.2%
Select financial related names showing weakness: LYG -2.6%, DB -2.1%, CS -1.9%, BCS -1.7%, SAN -1.6%, HSBC -1%,BAC -0.8%
Other news: MRNS -57.9% (announces ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo), BIOS -12% (commences common stock offering), SPHS -8.6% (modestly pulling back after Friday's gains), GWPH -2% (still checking), DANG -1.8% (Shanghai -3.5% overnight), BABA -1.1% (Shanghai -3.5% overnight), TRN -0.5% (enters into an Administrative Settlement and Compliance Agreement with the Federal Highway Administration pertaining to highway products)
Analyst comments: EMES -7.7% (downgraded to Underperform at DA Davidson), OSUR -4.2% (downgraded to Mkt Perform from Outperform at Raymond James), VOD -2.1% (downgraded to Neutral from Outperform at Macquarie), SAP -1.8% (downgraded to Underperform from Hold at Jefferies), BIDU -1.7% (downgraded to Neutral from Buy at Citigroup)
In reaction to disappointing earnings/guidance: SYUT -6.2%
Select financial related names showing weakness: LYG -2.6%, DB -2.1%, CS -1.9%, BCS -1.7%, SAN -1.6%, HSBC -1%,BAC -0.8%
Other news: MRNS -57.9% (announces ganaxolone did not meet the primary endpoint of demonstrating a statistically significant difference from placebo), BIOS -12% (commences common stock offering), SPHS -8.6% (modestly pulling back after Friday's gains), GWPH -2% (still checking), DANG -1.8% (Shanghai -3.5% overnight), BABA -1.1% (Shanghai -3.5% overnight), TRN -0.5% (enters into an Administrative Settlement and Compliance Agreement with the Federal Highway Administration pertaining to highway products)
Analyst comments: EMES -7.7% (downgraded to Underperform at DA Davidson), OSUR -4.2% (downgraded to Mkt Perform from Outperform at Raymond James), VOD -2.1% (downgraded to Neutral from Outperform at Macquarie), SAP -1.8% (downgraded to Underperform from Hold at Jefferies), BIDU -1.7% (downgraded to Neutral from Buy at Citigroup)
Gapping up
In reaction to strong earnings/guidance: SNSS +19.4%, SAIC +6.4%, STLD +3.1%, HNI +1.1%
M&A news: PWE +69.6% (confirmed $1.1 bln in asset sales, including sale of Saskatchewan assets for $975 mln), LNKD+47.2% (to be acquired my Microsoft (MSFT) for $196/share ), SYMC +4.2% (will acquire Blue Coat for ~$4.651 bln in cash),RDY +0.9% (to acquire Teva's (TEVA) portfolio of 8 ANDAs for $350 mln)
Select metals/mining stocks trading higher: MUX +6.8%, HMY +3.6%, AUY +3.2%, ABX +2.5%, GG +2.2%, NEM+2.1%, SLW +1.8%, GDX +1.8%, AU +1.6%
Other news: EBIO +79.1% (to grant an exclusive license to Roche (RHHBY) to develop/commercialize EBI-031; receives an upfront payment of $7.5 mln, along with potential milestone payments of up to $262.5 mln), SNSS +19.5% (presents updated results from an ongoing Phase 1b/2 trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia and high-risk myelodysplastic), AGIO +9.2% (presents data for Phase 2 DRIVE-PK study of AG-348 demonstrating rapid and sustained hemoglobin increases), SWHC +7.9% (speculation of tighter gun control laws; suggests ramp in near-term sales), MNKD +5.9% (presents Late-Breaking data Afrezza confirming faster onset and shorter duration of action compared to mealtime insulins), SUNW +5.5% (updated corporate presentation reaffirms FY16 target of $100 mln in revs vs the $103 mln single analyst estimate), TTNP +4.7% (receives $15 mln milestone payment from development and commercialization partner Braeburn Pharmaceuticals following FDA approval of Probuphine), RGR +4.3% (speculation of tighter gun control laws; suggests ramp in near-term sales), AMRN +4.2% (reports data for Vascepa that indicated reductions in potentially atherogenic lipid parameters), GALE +3.4% (presents combined safety data from its GALE-401 clinical trials), VRX+2.7% (CEO disclosed purchase of 202K shares worth ~$4.9 mln; Pershing Square affirms unchanged 9.0% active stake, updating on recent transactions), VICL +2.4% (insider purchase by CEO)
Analyst comments: ON +1.5% (upgraded to Overweight at Pacific Crest), ENDP +1.2% (upgraded to Neutral at Mizuho)
In reaction to strong earnings/guidance: SNSS +19.4%, SAIC +6.4%, STLD +3.1%, HNI +1.1%
M&A news: PWE +69.6% (confirmed $1.1 bln in asset sales, including sale of Saskatchewan assets for $975 mln), LNKD+47.2% (to be acquired my Microsoft (MSFT) for $196/share ), SYMC +4.2% (will acquire Blue Coat for ~$4.651 bln in cash),RDY +0.9% (to acquire Teva's (TEVA) portfolio of 8 ANDAs for $350 mln)
Select metals/mining stocks trading higher: MUX +6.8%, HMY +3.6%, AUY +3.2%, ABX +2.5%, GG +2.2%, NEM+2.1%, SLW +1.8%, GDX +1.8%, AU +1.6%
Other news: EBIO +79.1% (to grant an exclusive license to Roche (RHHBY) to develop/commercialize EBI-031; receives an upfront payment of $7.5 mln, along with potential milestone payments of up to $262.5 mln), SNSS +19.5% (presents updated results from an ongoing Phase 1b/2 trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia and high-risk myelodysplastic), AGIO +9.2% (presents data for Phase 2 DRIVE-PK study of AG-348 demonstrating rapid and sustained hemoglobin increases), SWHC +7.9% (speculation of tighter gun control laws; suggests ramp in near-term sales), MNKD +5.9% (presents Late-Breaking data Afrezza confirming faster onset and shorter duration of action compared to mealtime insulins), SUNW +5.5% (updated corporate presentation reaffirms FY16 target of $100 mln in revs vs the $103 mln single analyst estimate), TTNP +4.7% (receives $15 mln milestone payment from development and commercialization partner Braeburn Pharmaceuticals following FDA approval of Probuphine), RGR +4.3% (speculation of tighter gun control laws; suggests ramp in near-term sales), AMRN +4.2% (reports data for Vascepa that indicated reductions in potentially atherogenic lipid parameters), GALE +3.4% (presents combined safety data from its GALE-401 clinical trials), VRX+2.7% (CEO disclosed purchase of 202K shares worth ~$4.9 mln; Pershing Square affirms unchanged 9.0% active stake, updating on recent transactions), VICL +2.4% (insider purchase by CEO)
Analyst comments: ON +1.5% (upgraded to Overweight at Pacific Crest), ENDP +1.2% (upgraded to Neutral at Mizuho)
MSFT - Suspended News Pending
Schneider and Aveva restart deal talks
Schneider Electric, the French industrials group, is in renewed talks to acquire a majority stake in Aveva, the UK engineering software developer, as it makes another attempt to strike a deal with a potential value of around £2bn.
Two people close to the process said the companies have resumed discussions after their previously agreed deal collapsed in late December last year. One of the people added that the talks were advanced and agreement could be reached within weeks. But both people cautioned that there was no certainty that the discussions would lead to a deal.
Schneider Electric and Aveva declined to comment.
Their latest talks are said to concern a similar deal structure to the one they first announced in July last year, which was in effect a reverse takeover of Aveva by Schneider.
Under that proposed deal, which was terminated by mutual consent, Aveva would have swapped a majority stake in the combined business for Schneider’s industrial software unit, Schneider Software. The terms of the failed deal also included a £550m “control premium” to be paid to Aveva shareholders, equivalent to around 850p per share.
But, after six months of due diligence, Aveva said in December that “significant integration challenges were identified that could not be overcome without considerable additional risk and cost”.
On Monday, shares in Aveva rose out of negative territory and were trading 7 per cent higher, at £18.10, just after midday — with all the gains following the Financial Times’ first report of the talks. Schneider Electric shares were 1.3 per cent lower at €54.41, giving the company a market value of €32.1bn.
Schneider’s proposed combination with Aveva would follow its acquisition of another UK engineering IT group: Invensys. It bought the company in 2013 in a cash-and-share deal worth £3.4bn.
Early premarket gappers
Gapping up: PWE +75%, AGIO +11.2%, SWHC +6.3%, AUY +3.8%, MUX +3.4%, HMY +3.3%, ABX +3%, NEM +2.7%, GG+2.4%, RBS +2.3%, SLW +2.3%, GDX +2%, RGR +1.9%, VRX +1.7%, AU +1.6%
Gapping down: MT -6%, JKS -4.1%, SCTY -3.1%, VOD -2.3%, BIDU -2.3%, KMII -2.1%, GWPH -2%, SAN -1.9%, DANG-1.8%, BAC -1.7%, CS -1.6%, BP -1.4%, GILD -1.4%, BCS -1.4%, DB -1.3%, HSBC -1.3%, BABA -1.2%
Gapping down: MT -6%, JKS -4.1%, SCTY -3.1%, VOD -2.3%, BIDU -2.3%, KMII -2.1%, GWPH -2%, SAN -1.9%, DANG-1.8%, BAC -1.7%, CS -1.6%, BP -1.4%, GILD -1.4%, BCS -1.4%, DB -1.3%, HSBC -1.3%, BABA -1.2%
Oppenheimer reiterates Perform rating - Firm has argued that Apple is an interface expert at its core. They believe that great innovation in and implementation of human interface technologies are why its products consistently exceed consumers' expectation and surprise competitors. iPhone jump-started an entire mobile ecosystem, in which software and service companies thrive. But now, firm is seeing those companies threatening various aspects of Apple's platform. Today's Worldwide Developers Conference (WWDC) will give Apple a chance to reassert its competence as the likes of GOOG, FB, and AMZN work to beat Apple in its own game (interface). As firm outlined in long-term predictions on Apple, it is important Siri is opened up to third parties, and firm believes we will get this at WWDC.